What the research found

Researchers developed a simple formula—called the OEC Index—that estimates acute beta-cell insulin secretion capacity using routine oral glucose tolerance test (OGTT) data. The index combines early C-peptide measurements (the first 60 minutes after glucose ingestion) with glucose readings, adjusted for fasting glucose levels. This approach sidesteps the need for a hyperglycemic clamp, which is the gold-standard but technically complex procedure normally required to directly measure how quickly beta cells respond to glucose.

The formula was tested in two cohorts: one internal validation group of 257 participants and a separate external validation group of 70 participants, followed over multiple timepoints. Across both groups, the OEC Index predicted clamp-derived beta-cell response with moderate-to-good accuracy (R² values ranging from 0.39 to 0.61), and it outperformed three other OGTT-based indices at every measurement point.

Why it matters for you

If you're tracking glucose metabolism or concerned about metabolic health—whether managing insulin sensitivity, optimizing training nutrition, or monitoring progression toward insulin resistance—this matters because it offers a practical way to assess one critical piece of the puzzle: how well your pancreas can mount an acute insulin response.

Most MyKine users already perform or have access to OGTTs for glucose and insulin tracking. The OEC Index works with data you'd capture during a standard test, so there's no additional procedure needed. This makes it feasible to monitor beta-cell function over time without expensive clamp studies, useful if you're on interventions (peptides, metabolic training, dietary protocols) aimed at preserving or improving insulin secretion capacity.

That said, the moderate R² values indicate the index captures real variation but leaves room for individual noise—it's a useful signal, not a perfectly precise measurement.

Caveats

• Moderate predictive accuracy: the index explains roughly 40–60% of the variance in actual clamp-derived measures, meaning individual predictions carry meaningful uncertainty
• External validation was performed in a relatively small cohort (n=70) and only two datasets tested
• Longitudinal predictive performance declined over longer follow-up (24 months), suggesting the index may drift or be less reliable for very long-term tracking
• Both cohorts appear to be from metabolic/diabetes research populations; applicability to younger, healthier individuals unclear
• This is a formula-development study; no evidence yet that using OEC to guide intervention decisions improves outcomes